Clinical Trial

A Study Evaluating TRIV-509 in Atopic Dermatitis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 will cross over and receive 4 doses of the other study intervention. The study duration for individual participants is up to 57 weeks, including a Screening period of up to 30 days.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-28
notable Trial sites reduced: 44 -> 32 locations 2026-04-28
notable Trial sites expanded: 41 -> 44 locations 2026-04-03
Trial Details
NCT Number NCT07167758
Lead Sponsor Triveni Bio
Conditions Atopic Dermatitis
Enrollment 95 participants
Start Date 2025-08-26
Primary Completion 2026-10 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-27